PureTech Health plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRTC research report →
Range $44 – $70
Price Chart
About the company
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others. The Internal segment focuses on immunological, fibrotic, and lymphatic system mechanisms.
- CEO
- Robert William Henry Lyne
- IPO
- 2020
- Employees
- 56
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on PRTC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.23B
- P/E
- 149.65
- Fwd P/E
- 4.26
- PEG
- -0.22
- P/S
- 58.16
- P/B
- 0.94
- EV/EBITDA
- -2.65
- Div Yield
- 0.00%
- Gross Margin
- 48.09%
- Op Margin
- -1618.58%
- Net Margin
- 7.53%
- ROE
- 0.14%
- ROIC
- 0.85%
Latest fiscal year · YoY change
- Revenue
- $4.66M-3.5%
- Gross Profit
- $4.66M+270.6%
- Op Income
- $-98,525,000
- Net Income
- $-109,739,000-305.1%
- EPS
- $-46.00-2400.0%
- OCF Growth
- +36.5%
- FCF Growth
- +36.5%
- 52W High
- $19.92
- 52W Low
- $14.50
- 50D MA
- $16.94
- 200D MA
- $17.21
- Beta
- 0.76
- RSI (14)
- 52
- Avg Volume
- 9.19K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
PureTech said it executed on its capital-efficient hub-and-spoke strategy in H1 2026, with major portfolio milestones, $220 million of cash, and a runway at least through end-2028.· September 22, 2026
- Seaport completed a NASDAQ IPO, raising $250 million in gross proceeds, while Celea secured $180 million of external financing and moved into Phase III.
- Gallop received FDA Fast Track designation for LYT-200 in relapsed/refractory high-risk MDS and is preparing for a Phase II trial once external financing is in place.
- PureTech ended June 2026 with about $220 million of cash, cash equivalents and short-term investments and reiterated runway through at least end-2028.
- Management said PureTech-level operating expenses were $55.9 million in the first half of 2026 versus $49.8 million a year earlier, and expects a meaningful reduction going forward as Celea costs move off the parent P&L.
- The company also said it is advancing new LIFE-model innovation programs and expects to share more detail in the first half of 2027.
PureTech reported first-half 2026 consolidated operating expenses of $55.9 million versus $49.8 million in the same period of 2025, with the increase tied to R&D spending for Celea’s Phase III preparation. PureTech ended June 2026 with approximately $220 million of cash, cash equivalents and short-term investments at the PureTech level, versus $277.1 million at year-end 2025; on a consolidated basis, cash, cash equivalents and short-term investments were $220.1 million versus $277.3 million at year-end 2025. Management also said it reserved $70 million for possible future investment into Celea and reiterated operational runway at least through the end of 2028, even after assuming full deployment of that reserve. Forward-looking guidance was that cash burn on a clean basis, including overhead and innovation spend, should run about $30 million to $40 million a year going forward, down from roughly $90 million a year when later-stage clinical programs were run internally. The company also said it expects a significant reduction in overall operating expenses moving forward as Celea-related expenses shift out of PureTech.
Robert Lyne framed the half year as evidence that PureTech’s refined strategy is working: external capital is funding late-stage development at the spoke companies while PureTech preserves balance-sheet strength and retains upside through equity, milestones, and royalties. He emphasized that the company wants to be more disciplined about capital allocation, keep sufficient runway, and increasingly return capital to shareholders when appropriate. His tone was confident and pragmatic, repeatedly pointing to the model’s ability to lower risk concentration and make shareholder participation more direct as value is realized.
Rob Lyne’s financial commentary focused on liquidity, declining parent-level spend, and capital discipline. He highlighted PureTech’s $220 million cash balance, the $70 million Celea reserve, and the runway through end-2028, while noting that the $17.5 million balancing contribution would come out of the cash figure mentioned. He also explained that first-half OpEx was elevated because of Celea’s Phase III prep, but said future expenses should fall materially now that those costs sit at Celea, with expected annual cash burn of $30 million to $40 million versus about $90 million previously. He also said the company wants to avoid holding excessive cash and will weigh future deployment between runway, portfolio investment, and shareholder returns.
Analysts pressed on Gallop’s STRIDE-MDS trial design, including whether biomarkers would be used, and management said the FDA was comfortable with a mutation-agnostic approach and no biomarker selection is currently planned. They also asked about timing, with Eric Elenko saying the study would start after external financing and could take a little under 3 years, or around 30 to 33 months depending on sites and recruitment. On financing, management said it is considering multiple options for Gallop, including equity and partnership structures, and wants to complete financing by the first half of next year. Questions also covered whether Celea might become more platform-like like Seaport; management said Celea is currently a single-asset IPF company, though additional assets could be considered later as it matures.
The bull case from this call is that PureTech is converting its platform into outside-funded value creation while protecting its own balance sheet. Seaport’s IPO, Celea’s financing and Phase III start, and Gallop’s Fast Track status all suggest the model is producing repeatable, de-risked assets with real external validation. Management also sounded confident that the innovation engine is replenishing the pipeline, with at least three concept-stage programs per year and more detail expected in 1H 2027.
The main risks are execution and financing: Gallop still needs external capital before STRIDE-MDS can start, and management expects Celea will need additional money to finish Phase III. The company also noted that Cobenfy-related economics have been revised down versus the prior update, reducing a potential future value stream even though some upside remains. More broadly, the new programs are still preclinical/early and management did not provide near-term clinical data or specific assets yet.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 64.6%
- Shares Outstanding
- 24.34M
- Float Shares
- 15.72M
of shares held by institutions
5 13F filers
Held by 1 ETFs
Biggest fund positions in PRTC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 13, 22 | PureTech Health plc | other | 0 |
| Jan 13, 22 | PureTech Health plc | other | 0 |
| Jan 13, 22 | PureTech Health plc | other | 0 |
| Jan 13, 22 | PureTech Health plc | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PRTC coverage
Recent articles, reports, and earnings notes.
No research on PRTC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PRTC report →PureTech Health H1 Earnings Call Highlights
defenseworld.net · Sep 22
PureTech Health: Results of Annual General Meeting
businesswire.com · Jun 10
PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference
businesswire.com · May 13
PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
proactiveinvestors.com · May 1
PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
proactiveinvestors.co.uk · May 1
PureTech Health plc (PRTC) Q4 2025 Earnings Call Transcript
seekingalpha.com · Apr 29
PureTech Announces Annual Results for Year Ended December 31, 2025
businesswire.com · Apr 29
PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange
businesswire.com · Apr 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.